trans-4-methacryloyloxyazobenzene | 128818-49-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 偶氮苯
• 英文名称: trans-4-methacryloyloxyazobenzene
• CAS: 128818-49-5
• 化学式: C₁₆H₁₄N₂O₂
• 分子量: 266.299
• InChiKey: IGCJKJTYHIDZJN-ISLYRVAYSA-N

物化性质

• 熔点：
  110 °C(Solv: ligroine (8032-32-4))
• 沸点：
  420.1±24.0 °C(Predicted)
• 密度：
  1.08±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.58
• 重原子数：
  20.0
• 可旋转键数：
  4.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  51.02
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为产物：
  描述：

  甲基丙烯酰氯 、 (E)-4-Phenylazophenol 在 2,6-二叔丁基-4-甲基苯酚 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 以70%的产率得到trans-4-methacryloyloxyazobenzene
  参考文献：
  名称：

  Synthesis of Azobenzene-Based Polymers and the in-Situ Characterization of Their Photoviscosity Effects

  摘要：

  A new in-situ technique for the measurement of photoviscosity effects in polymer solutions has been developed using a custom-modified, cone-and-plate rheometer. The new technique permits simultaneous irradiation of the polymer solution and continuous measurement of its viscosity in a temperature-controlled environment. An additional benefit of the technique is the greatly reduced sample volume compared to traditional capillary viscometers. However, adequate measures have to be taken to minimize the evaporation of the sample solution and to maintain the required temperature. Copolymers of methyl methacrylate and azobenzene monomers with a chromophore in the side chain have been synthesized and characterized using the new technique. This polymer exhibits a photoviscosity effect when exposed to UV irradiation (lambda = 365 nm), with the reduced specific viscosity eta(sp)/c of the polymer being up to 77% lower than in the dark. However, the magnitude of the photoinduced change in eta(sp)/c was found to increase with the number of azobenzene units in the polymer chain, and the greatest effect was shown by a polymer with 42 mol % azobenzene loading.

  DOI：

  10.1021/ma049905d

文献信息

• [EN] ENCAPSULATES<br/>[FR] PRODUITS ENCAPSULÉS
  申请人：PROCTER & GAMBLE

  公开号：WO2013022949A1

  公开（公告）日：2013-02-14

  The present application relates to encapsulates, compositions, products comprising such encapsulates, and processes for making and using such encapsulates. Such encapsulates comprise a core comprising a perfume and a shell that encapsulates said core, such encapsulates may optionally comprise a parametric balancing agent, such shell comprising one or more azobenzene moieties.

  本申请涉及封装体、组合物、包含这种封装体的产品，以及制备和使用这种封装体的方法。这种封装体包括一个包含香水的核心和封装该核心的壳，这种封装体可以选择性地包含一个参数平衡剂，该壳包括一个或多个偶氮苯基团。
• POLYMERIZABLE YELLOW DYE FOR MANUFACTURING OPHTHALMIC LENS
  申请人：BenQ Materials Corporation

  公开号：US20140378672A1

  公开（公告）日：2014-12-25

  A polymerizable yellow dye which is used to block or lower the intensity of blue light transmitted through ophthalmic lenses and is represented by the following formula (I): wherein R 1 is hydrogen or —NHCOCH 3 ; R 2 is hydrogen or C 1 -C 3 alkyl groups; R 3 and R 4 are independently hydrogen or —OCO—R 5 , wherein R 5 is isopropenyl group or a substituted isopropenyl group represented as —R 6 —(R 7 O) n —COC(CH 3 )CH 2 , R 6 is NH or R 7 is C 1 -C 5 alkylene groups and n is an integer of 1-40.

  一种可聚合的黄色染料，用于阻挡或降低透过眼镜的蓝光强度，其化学式如下（I）：其中R1是氢或—NHCO ；R2是氢或C1-C3烷基基团；R3和R4独立地是氢或—OCO—R5，其中R5是异丙烯基或表示为—R6—（R7O）n—COC(CH3)CH2的取代异丙烯基，R6是NH或R7是C1-C5烷基基团，n为1-40的整数。
• PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE
  申请人：Kwak Taehwan

  公开号：US20100239674A1

  公开（公告）日：2010-09-23

  Disclosed is a pharmaceutical composition for the treatment and/or prevention of erectile dysfunction, comprising (a) a therapeutically effective amount of a compound represented by Formula 1 or 2, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.

  本发明公开了一种用于治疗和/或预防勃起功能障碍的药物组合物，包括（a）按照式1或式2表示的化合物的治疗有效量，以及（b）药学上可接受的载体、稀释剂或赋形剂，或其任意组合。
• PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF RESTENOSIS
  申请人：Kwak Taehwan

  公开号：US20100255054A1

  公开（公告）日：2010-10-07

  Provided is a pharmaceutical composition for the treatment and/or prevention of restenosis including (a) a therapeutically effective amount of a particular compound represented by Formula 1 and 2, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.

  提供了一种药物组合物，用于治疗和/或预防再狭窄，包括(a) 一定量的化合物，其化学式为1和2，或其药学上可接受的盐、前药、溶剂或异构体，且具有治疗效果，以及(b) 药学上可接受的载体、稀释剂或赋形剂，或任何其组合。
• METHOD FOR THE TREATMENT AND PREVENTION OF ERECTILE DYSFUNCTION
  申请人：KWAK Taehwan

  公开号：US20120114714A1

  公开（公告）日：2012-05-10

  Disclosed is a pharmaceutical composition for the treatment and/or prevention of erectile dysfunction, comprising (a) a therapeutically effective amount of a compound represented by Formula 1 or 2, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.

  本发明公开了一种治疗和/或预防勃起功能障碍的药物组合物，包括（a）公式1或2所代表的化合物的治疗有效量，以及（b）药学上可接受的载体、稀释剂或赋形剂或其组合。